InMed Q3 FY2022 net loss $10.7M; revenue $0.6M from BayMedica; board adds Baldasare

InMed Pharmaceuticals Inc.

2023-Q3 EPS reported -$20.13 revenue$574,677

Net loss for 9 months ended Mar 31, 2022: $10.7M ($0.81/share) vs $6.9M ($1.11/share) prior year.
BayMedica generated $0.6M revenue from rare cannabinoid sales; gross profit $0.3M.
Cash, cash equivalents and short-term investments $5.9M vs $7.4M at June 30, 2021.
Appointed Bryan Baldasare to Board of Directors; board expanded to six members.
Phase 2 trial of INM-755 for EB continues; pIND for INM-088 glaucoma aligns with FDA.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Bryan Baldasare

director

INM · InMed Pharmaceuticals Inc.

Effective: 2022-05-12
Filed: May 18, 2022, 7:59 PM ET

On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Bryan Baldasare was appointed as director at InMed Pharmaceuticals Inc..

Action: appointed
Role: director

Exact text from the filing

On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.

View on SEC.gov

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-027887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.